Phase 2 N=10 Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla
Type 1 Diabetes
Primary: Brain Glycogen Turnover Rate — 0.31; 0.28 mg/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Aldosterone and Glucose Homeostasis
Diabetes Mellitus
Primary: Insulin Secretion — 48.9; 37.6; 51.8; 34.4 uU/mL
N/A N=90 Exercise Training and Glucose Metabolism in Aging
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance (Prediabetes)
Primary: Baseline Glucose Utilization — 0.0062; 0.0035 µmol/kgFFM/pmol insulin/min
Phase 3 N=12 The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
Healthy
Primary: Endogenous Glucose Production (EGP) — 4.99; 5.02; 6.82; 5.52 umol/kg/min
N/A N=10 Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A
Diabetes Mellitus, Type 1
Primary: Glutathione Concentration — 541; 551 umol/L
Phase 1 N=14 Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Glucose Transporter Type 1 Deficiency Syndrome · GLUT1 Deficiency Syndrome
Primary: Number of Participants With Reduction in Spike-wave Fraction of the EEG Recording Time — 13 Participants
Phase 1 N=10 The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
Healthy Participants
Primary: Rates of Hepatic Mitochondrial Oxidation — 262; 149 micromol/min
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
N/A N=82 Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
N/A N=19 Post-Prandial Liver Glucose Metabolism in PCOS
Polycystic Ovarian Syndrome · Obesity · Hepatic Steatosis
Primary: Hepatic Fat Fraction — 8.35 Percent
N/A N=40 Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B
Diabetes Mellitus, Type 1
Primary: Glutathione Concentration — 706; 734 umol/L
N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
Phase 4 N=36 Effects of Metformin on Hepatic FFA Metabolism
Type 2 Diabetes · Dyslipidemia
Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min
N/A N=96 Glucose and Lipid Metabolism on Antipsychotic Medication
Schizophrenia · Schizoaffective Disorder · Type 2 Diabetes Mellitus
Primary: DEXA Total Fat — 32.24; 27.66; 28.83; 31.60 kilograms of body fat — p=0.002
N/A N=20 Hepatic Mitochondrial Function in Youth
Hepatic Steatosis · Bariatric Surgery Candidate · Adolescent Obesity
Primary: Change in Percentage of Liver Fat Per MRI — -13.93 percentage of liver fat
N/A N=7 Vagal Nerve Stimulation and Glucose Metabolism
Type 2 Diabetes · Obesity · Gastric Emptying
Primary: Disposition Index — 703; 532 10^-14dl/kg/min^2 per pmol/l
Phase 4 N=72 Empagliflozin and Hepatic Glucose Metabolism
Hepatic Glucose Metabolism
Primary: Effect of Empagliflozin on Autonomic Nervous System — 480; 621; 355; 635 ng/min
N/A N=33 The Effects of Spasticity on Glucose Metabolism in Individuals With Spinal Cord Injury
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
Phase 1 N=11 Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
Metabolic Diseases
Primary: Oral Glucose Sensitivity Index (Kisspeptin-Placebo) — 517; 521 ml min-1m-2
N/A N=44 Effect of Fermentable Carbohydrate on Glucose Homeostasis
Prediabetes
Primary: Glycaemic Control — -0.23; 0.44 mmol//l — p=0.005
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 4 N=44 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
Metabolic Syndrome
Primary: Insulin Secretion — 293.1; 234.7; 330.8; 300.4 uU/mL*10min
Phase 4 N=5 Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
Hepatitis B
Primary: Differences in Blood Glucose Levels as Measured by GNS-POC, GS-POC and Venous Blood Prior to and After HBIG Injection — -3.2; 6.0; 56.6; -2.6 mg/dL — p=0.59
N/A N=33 Training Effects on Skeletal Muscle Fatty Acid Metabolism
Healthy Volunteers
Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
Phase 3 N=30 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Type II; Diabetes
Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless